Endava plc Endava (DAVA) delivered a classic "yes, but" earnings report this week. The IT services company managed to beat profit expectations handily, but its top line came up short, leading analysts to sharpen their pencils and lower their forecasts.

Here's the scorecard: for the first quarter, Endava posted adjusted earnings of 20 cents per share, which was more than double the 8 cents per share that Wall Street was looking for. That's the good news. The not-so-good news is that quarterly sales came in at $240.314 million, missing the consensus estimate of $245.910 million.

So, what happened? According to CEO John Cotterell, two main things threw a wrench in the works. "The first quarter results were lower than guided primarily due to an unexpected credit made to a client that arose subsequent to our last earnings call as well as certain non large strategic pipeline opportunities that did not convert into revenue during the quarter as anticipated," he explained.

In other words, they had to give some money back to a client (never fun), and some deals they were counting on just didn't close in time. It's the kind of quarter that can make any CFO wince.

But Cotterell wasn't all doom and gloom. He pointed to a significant bright spot: "While these factors weighed on our performance, our ability to secure a multi-year strategic relationship with a leading payments company of up to $100 million demonstrates the strength of our client relationships." That's a hefty new deal, and it suggests the underlying business engine might be healthier than a single quarter's revenue miss implies.

Looking ahead, Endava's guidance for the second quarter calls for adjusted earnings between 20 and 23 cents per share on sales ranging from $241.410 million to $245.456 million.

The market's initial reaction was interesting. Despite the revenue miss and the analyst cuts we're about to get to, Endava shares actually gained 2.2% to trade at $7.10 on Wednesday. Sometimes, when bad news is fully expected, even a mixed report can be enough to lift a stock if investors were braced for something worse.

Speaking of those analyst cuts, the reaction from Wall Street's research desks was swift and uniform: maintain the rating, but lower the target price. It's the financial equivalent of saying, "We still believe in you, kid, but you're not going to the moon as fast as we thought."

Needham analyst Mayank Tandon kept his Buy rating on the stock but slashed his price target from $12 down to $9. Over at Guggenheim, analyst Jonathan Lee also maintained a Buy, though he brought his target down from a lofty $18 to a more grounded $15. Finally, JP Morgan's Puneet Jain stuck with a Neutral rating while lowering his target from $13 to $10.

The story here isn't just about a miss. It's about a company navigating client-specific issues and deal timing, all while landing a major new strategic partnership. The analysts have recalibrated their expectations, but the stock's positive move post-earnings suggests some investors might see the $100 million deal and the profit beat as signs that Endava's core story remains intact, even if the journey just got a bit bumpier.